| Open Document File Size: 585,09 KBShare Result on Facebook
City Research Triangle Park / / Company Adherex Technologies Inc. / / Continent North America / / Country Guinea / United States / / Event FDA Phase / / Facility DNA complex / / IndustryTerm chemical reducing agent / chemical species / prevention of ototoxicity induced by platinum cancer / / MedicalCondition cyanide poisoning / pediatric liver cancer / childhood cancers / target cancer / neuroblastoma / osteogenic sarcoma / Standard Risk Hepatoblastoma / platinum-associated hearing loss / rat subcutaneous tumor / hearing loss / germ cell tumors / cancers / Tumor / extracranial germ cell tumors / cancer / nasopharyngeal carcinoma / tumors / cisplatin-induced hearing loss / different cancers / hepatocellular carcinoma / human neuroblastoma xenograft cell lines / SMS-SAN neuroblastoma xenografts / disseminated disease / acute cyanide poisoning / DAOY medulloblastoma cells / liver cancer / diseases / Carboplatin-Treated Nude Rats Tumor / medulloblastoma / hepatoblastoma / Cells In Vitro With respect to tumor / platinum cancer / Severe Combined Immuno Deficiency / intracerebral human lung carcinoma / rhabdomyosarcoma / / MedicalTreatment chemotherapy / radiotherapy / surgery / radiation / / Organization STS administration / Delayed administration / Delayed Administration of Sodium Thiosulfate / Briefing Document Pediatric Subcommittee of ODAC / United States Army / FDA / Oncologic Drugs Advisory Committee / Advisory Committee / Oncology Drug Advisory Committee / Pediatric Subcommittee / / Product Carboplatin / Cisplatin / Sodium Thiosulfate / etoposide / STS / furosemide / ACCL0431 / platinum / Platinum compounds / / ProvinceOrState North Carolina / / Technology radiation / SMS / cell signaling / Pharmacokinetics / Chemotherapy / SAN / /
SocialTag |
Sodium Thiosulfate Injection, USP, 25% Briefing Document for The Pediatric Subcommittee of the Oncologic Drugs Advisory Committee 01 November 2011